BPIFB1

BPIFB1 is a secreted glycoprotein of the upper airway innate immune system that functions as a modulator of inflammatory signaling, mucus homeostasis, and tumor suppression. Produced by goblet cells and submucosal glands, BPIFB1 is secreted into airway surface liquid where it integrates into the MUC5B-containing mucus network and is required for effective mucociliary clearance; loss of BPIFB1 elevates MUC5B levels and alters mucus biophysical properties without affecting ion transport or ciliary beat frequency (PMID:20237794, PMID:28851744, PMID:37847709). BPIFB1 attenuates LPS-induced inflammation through TLR4-dependent suppression of MyD88/TRAF6/NF-κB and MAPK signaling, and in nasopharyngeal carcinoma it acts as a tumor suppressor by inhibiting JAK2/STAT3, FAK/Src/ERK, and JNK/AP-1 pathways through interactions with VTN, VIM, and PHB1—stabilizing PHB1 by competitively blocking TRIM21-mediated ubiquitination—and by reprogramming tumor metabolism via the PHB1-p53/c-Myc glycolytic axis and GLUT1-dependent H3K27 acetylation of vasculogenic mimicry genes (PMID:21900486, PMID:23708661, PMID:29123267, PMID:30886235, PMID:34725462, PMID:36382614). Autoantibodies against BPIFB1 are associated with interstitial lung disease in autoimmune polyendocrinopathy syndrome type 1 (APS1), where Aire deficiency drives loss of thymic tolerance to this lung-restricted antigen (PMID:24107778).

1. 2010 High

   Establishing where BPIFB1 protein is expressed and secreted resolved the question of which airway cell types produce this innate defense molecule and in what form it reaches the airway surface.

   Evidence Immunohistochemistry with affinity-purified antibodies and western blotting of BAL fluid and primary airway epithelial cultures identified goblet cells and submucosal glands as sources and two glycosylated secreted isoforms

   PMID:20237794

   Open questions at the time

   • Post-translational modification sites not mapped
   • Receptor or binding partner on target cells not identified
   • Regulation of secretion not characterized
2. 2011 Medium

   Demonstrating that BPIFB1 attenuates LPS-induced inflammation via TLR4 but not TLR2 established its receptor specificity as an innate immune modulator, answering how a secreted BPIF family member interfaces with pattern-recognition signaling.

   Evidence In vitro LPS stimulation assays with BPIFB1 treatment showing TLR4-dependent attenuation; immunostaining of duodenal biopsies during V. cholerae infection

   PMID:21900486

   Open questions at the time

   • Direct binding to LPS or TLR4 not demonstrated
   • Mechanism of CD14/TLR4 downregulation unknown
   • In vivo functional relevance in airway infection not tested at this stage
3. 2013 High

   Multiple studies established BPIFB1 as a tumor suppressor in nasopharyngeal carcinoma by showing it inhibits two major oncogenic pathways—JAK2/STAT3 and MAPK/ERK—and their downstream cell cycle effectors, resolving the question of whether this innate immune protein has anti-proliferative activity.

   Evidence Stable overexpression in NPC cell lines with western blotting, microarray, cell cycle analysis, and in vivo tumor implantation models

   PMID:23650533 PMID:23708661

   Open questions at the time

   • Direct molecular target mediating pathway suppression not identified
   • Relevance beyond NPC not established
   • Whether endogenous BPIFB1 levels are tumor-suppressive in patients unclear
4. 2013 Medium

   Dissection of BPIFB1's anti-inflammatory mechanism in macrophages revealed it reduces CD14, TLR4, MyD88, TRAF6, and NF-κB signaling along with ERK1/2, p38, and Akt phosphorylation, providing a detailed pathway map of its LPS-dampening activity.

   Evidence siRNA knockdown of pathway components and kinase inhibitors in RAW264.7 macrophages treated with BPIFB1 and LPS

   PMID:23746244

   Open questions at the time

   • Whether BPIFB1 acts extracellularly (e.g., sequestering LPS) or intracellularly not resolved
   • Single laboratory finding
   • Direct physical interaction with any pathway component not shown
5. 2013 Medium

   Discovery that anti-BPIFB1 autoantibodies are present in 100% of APS1-ILD patients and that Aire deficiency drives autoimmunity against this lung-restricted antigen established BPIFB1 as a clinically relevant autoantigen in interstitial lung disease.

   Evidence Autoantibody screening in APS1 cohorts, Aire−/− mouse model, immunization experiments inducing ILD

   PMID:24107778

   Open questions at the time

   • Whether autoantibodies are pathogenic or merely biomarkers not fully resolved in humans
   • Mechanism by which loss of BPIFB1 function causes ILD pathology unknown
   • Prevalence in non-APS1 ILD incompletely defined
6. 2017 High

   Identification of VTN and VIM as direct BPIFB1 binding partners answered the long-standing question of which molecular interactors mediate BPIFB1's anti-tumor effects, linking it to FAK/Src/ERK suppression and EMT inhibition.

   Evidence Co-immunoprecipitation coupled with mass spectrometry, immunofluorescence colocalization, in vitro migration/invasion assays, and in vivo lung metastasis model

   PMID:29123267

   Open questions at the time

   • Binding domains on BPIFB1 for VTN/VIM not mapped
   • Whether this interaction occurs in normal airway physiology unknown
   • Structural basis of competitive disruption of VTN–integrin αV not defined
7. 2017 High

   Genetic evidence from Bpifb1 knockout mice established that BPIFB1 is a trans regulator of MUC5B protein levels, connecting a BPIF family member to mucin homeostasis for the first time.

   Evidence QTL mapping in Collaborative Cross mice, Bpifb1 KO model showing elevated MUC5B, allergen challenge experiments

   PMID:28851744

   Open questions at the time

   • Mechanism by which BPIFB1 regulates MUC5B expression or stability not defined
   • Whether the effect is transcriptional or post-translational unclear
   • Human genetic evidence for this regulatory axis lacking
8. 2019 High

   Discovery that BPIFB1 stabilizes PHB1 by competitively blocking TRIM21-mediated ubiquitination provided a direct biochemical mechanism for tumor suppression, resolving how BPIFB1 controls NF-κB activity at the post-translational level.

   Evidence Co-immunoprecipitation, in vivo ubiquitination assays, competitive binding experiments, NF-κB reporter assays in NPC cells

   PMID:30886235

   Open questions at the time

   • Binding interface between BPIFB1, PHB1, and TRIM21 not structurally resolved
   • Physiological relevance in non-tumor airway cells not tested
   • Whether other E3 ligases also regulate PHB1 in this context unknown
9. 2021 High

   Linking BPIFB1 to vasculogenic mimicry via JNK/AP-1-driven GLUT1 transcription and H3K27ac-mediated epigenetic reprogramming revealed a metabolic–epigenetic tumor suppressive axis, answering how BPIFB1 controls tumor angiogenesis.

   Evidence BPIFB1 overexpression/knockdown, ChIP for H3K27ac at VEGFA/VE-cadherin/MMP2 promoters, luciferase reporters, metabolic flux assays in NPC cells

   PMID:34725462

   Open questions at the time

   • Whether acetyl-CoA reduction is sufficient to explain H3K27ac changes not independently confirmed
   • Role of other histone marks not examined
   • In vivo validation of vasculogenic mimicry suppression limited
10. 2022 Medium

    Positioning BPIFB1 as a circadian-regulated downstream effector of PER2 in alveolar type 2 cells expanded its functional context beyond innate defense to circadian lung protection during bacterial injury.

    Evidence Cell-type-specific Per2 KO mice, intense light therapy, genome-wide mRNA array, nobiletin treatment, P. aeruginosa acute lung injury model

    PMID:35272486

    Open questions at the time

    • Direct transcriptional regulation of BPIFB1 by PER2 not demonstrated (e.g., no PER2 ChIP at BPIFB1 locus)
    • Mechanism by which BPIFB1 mediates lung protection in this model undefined
    • Single study without independent replication
11. 2022 Medium

    Demonstrating that BPIFB1 reprograms NPC metabolism from glycolysis to oxidative phosphorylation through the PHB1-p53/c-Myc axis provided a unified metabolic mechanism linking the previously identified PHB1-stabilizing activity to tumor suppression.

    Evidence BPIFB1 and PHB1 overexpression, subcellular fractionation showing phospho-PHB1 nuclear translocation via 14-3-3σ, glycolysis/OXPHOS assays

    PMID:36382614

    Open questions at the time

    • Direct kinase phosphorylating PHB1 in this context not identified
    • Whether metabolic switch occurs in non-NPC tumor types untested
    • Single laboratory study
12. 2023 High

    Knockout studies proved BPIFB1 is required for effective mucociliary clearance and colocalizes with MUC5B in secretory granules and the mucus gel, establishing its structural role in airway mucus beyond regulation of MUC5B levels.

    Evidence Bpifb1 KO mice with in vivo mucociliary clearance measurement, in vitro airway cultures, immunofluorescence colocalization, mucus biophysical assays

    PMID:37847709

    Open questions at the time

    • Molecular basis of how BPIFB1 alters mucus biophysical properties not defined
    • Whether BPIFB1 directly cross-links mucin polymers or acts indirectly unknown
    • Human airway relevance of KO phenotype not confirmed
13. 2024 Medium

    Discovery that BPIFB1 suppresses PD-L1 via STAT1 repression and is targeted by EBV-encoded miR-BART4 linked its tumor-suppressive function to immune evasion in EBV-driven NPC, answering how EBV neutralizes BPIFB1.

    Evidence Luciferase reporter assays, ChIP, flow cytometry for CD8+ T-cell apoptosis and activation, overexpression in NPC cells

    PMID:38467887

    Open questions at the time

    • In vivo immune evasion phenotype driven by miR-BART4/BPIFB1 axis not demonstrated
    • Direct binding of BPIFB1 to STAT1 promoter elements not shown
    • Whether anti-PD-L1 axis operates outside EBV-positive NPC unclear

• The molecular mechanism by which BPIFB1 integrates into the mucus gel to regulate its biophysical properties, the structural basis of its interactions with PHB1/VTN/VIM, and whether its tumor-suppressive functions have physiological relevance beyond NPC remain unresolved.
• No crystal or cryo-EM structure of BPIFB1 or its complexes
• Direct LPS-binding activity not demonstrated biochemically
• Whether BPIFB1 tumor-suppressive pathways operate in normal airway epithelium unknown